Adding Fat to the Fire: Does Lipidated IL-22 Promote Mucosal Healing in Patients with Inflammatory Bowel Disease Treated with Immunomodulators?

Affiliations

Editorial

Johan Dabrosin Söderholm. Dig Dis Sci. 2025 Nov.

. 2025 Nov;70(11):3608-3610.

doi: 10.1007/s10620-025-09169-7. Epub 2025 Jun 23.

¹ Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. johan.d.soderholm@liu.se.

No abstract available

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no competing interests.

1. Danese S, Solitano V, Jairath V et al. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut. 2022;71:2380–2387. - DOI - PubMed
1. Stoy S, D′Alessio S, Sandahl TD et al. Lipidated IL-22 alone or combined with immunomodulatory agents improves disease endpoints and promotes mucosal healing in a mouse model of chronic dextran sodium sulfate-induced colitis. Dig Dis Sci. 2025. https://doi.org/10.1007/s10620-025-09007-w . - DOI - PubMed - PMC
1. Graham DB, Xavier RJ. Pathway paradigms revealed from the genetics of inflammatory bowel disease. Nature. 2020;578:527–539. - DOI - PubMed - PMC
1. Turpin W, Lee SH, Raygoza Garay JA et al. Increased intestinal permeability is associated with later development of Crohn’s disease. Gastroenterology. 2020;159:2092-2100 e5. - DOI - PubMed
1. Keir M, Yi Y, Lu T et al. The role of IL-22 in intestinal health and disease. J Exp Med. 2020;217:e20192195. - DOI - PubMed - PMC